Filtered By:
Specialty: Cardiology
Drug: SGLT2 Inhibitors
This page shows you your search results in order of date.
Order by Relevance | Date
Total 302 results found since Jan 2013.
Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes
CONCLUSION: These findings indicate that dapagliflozin protects against endothelial cell senescence by regulating SIRT1 signaling in diabetic mice.PMID:37664712 | PMC:PMC10469571 | DOI:10.1016/j.heliyon.2023.e19152
Source: Atherosclerosis - September 4, 2023 Category: Cardiology Authors: Shi Tai Ying Zhou Liyao Fu Huiqing Ding Yuying Zhou Zhiyi Yin Rukai Yang Zhenjiang Liu Shenghua Zhou Source Type: research
Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm
CONCLUSION: SGLT1 and SGLT2 could be potential biomarkers of adrenal injury in atherosclerosis under chronic stress.PMID:37663275 | PMC:PMC10474830 | DOI:10.7717/peerj.15647
Source: Atherosclerosis - September 4, 2023 Category: Cardiology Authors: Jianyi Li Lingbing Meng Dishan Wu Hongxuan Xu Xing Hu Gaifeng Hu Yuhui Chen Jiapei Xu Tao Gong Deping Liu Source Type: research
Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes
CONCLUSION: These findings indicate that dapagliflozin protects against endothelial cell senescence by regulating SIRT1 signaling in diabetic mice.PMID:37664712 | PMC:PMC10469571 | DOI:10.1016/j.heliyon.2023.e19152
Source: Atherosclerosis - September 4, 2023 Category: Cardiology Authors: Shi Tai Ying Zhou Liyao Fu Huiqing Ding Yuying Zhou Zhiyi Yin Rukai Yang Zhenjiang Liu Shenghua Zhou Source Type: research
Adrenal SGLT1 or SGLT2 as predictors of atherosclerosis under chronic stress based on a computer algorithm
CONCLUSION: SGLT1 and SGLT2 could be potential biomarkers of adrenal injury in atherosclerosis under chronic stress.PMID:37663275 | PMC:PMC10474830 | DOI:10.7717/peerj.15647
Source: Atherosclerosis - September 4, 2023 Category: Cardiology Authors: Jianyi Li Lingbing Meng Dishan Wu Hongxuan Xu Xing Hu Gaifeng Hu Yuhui Chen Jiapei Xu Tao Gong Deping Liu Source Type: research
SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms
Am J Cardiovasc Drugs. 2023 Aug 24. doi: 10.1007/s40256-023-00602-8. Online ahead of print.ABSTRACTPopulation aging combined with higher susceptibility to cardiovascular diseases in older adults is increasing the incidence of conditions such as atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, myocardial fibrosis, arrhythmia, and hypertension. sodium-glucose cotransporter 2 inhibitors (SGLT2i) were originally developed as a novel oral drug for patients with type 2 diabetes mellitus. Unexpectedly, recent studies have shown that, beyond their effect on hyperglycemia, SGLT2i also have a variety of...
Source: Atherosclerosis - August 24, 2023 Category: Cardiology Authors: Yali Zhang Yufeng He Siqi Liu Li Deng Yumei Zuo Keming Huang Bin Liao Guang Li Jian Feng Source Type: research
SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type
CONCLUSION: In meta-analyses, SGLT2-inhibition increased total, LDL, and HDL cholesterol and decreased triglycerides. Effect sizes varied slightly by drug dose and ethnicity but were generally robust by drug type.PMID:37582673 | DOI:10.1016/j.atherosclerosis.2023.117236
Source: Atherosclerosis - August 15, 2023 Category: Cardiology Authors: Louise E Bechmann Frida Emanuelsson B ørge G Nordestgaard Marianne Benn Source Type: research
Sodium-Glucose Cotransporter-2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Trials and Systematic Review
Conclusions SGLT2 inhibitors significantly reduced atherosclerotic MACEs in subjects having both chronic kidney disease and type 2 diabetes without established ASCVD.PMID:37581396 | DOI:10.1161/JAHA.123.030578
Source: Atherosclerosis - August 15, 2023 Category: Cardiology Authors: Hammad Rahman Safi U Khan Ahmad N Lone Priyanka Ghosh Mahathi Kunduru Saurabh Sharma Sudhakar Sattur Edo Kaluski Source Type: research
SGLT2 inhibitor canagliflozin alleviates vascular calcification through suppression of NLRP3 inflammasome
CONCLUSIONS: Our study for the first time demonstrates that CANA exerts a protective effect on vascular calcification at least partially via suppressing NLRP3 signaling pathway. Therefore, supplementation of CANA as well as inhibition of NLRP3 inflammasome presents a potential therapy for vascular calcification.PMID:37523743 | DOI:10.1093/cvr/cvad119
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: An Chen Zirong Lan Li Li Luting Xie Xiaoyu Liu Xiulin Yang Siyi Wang Qingchun Liang Qianqian Dong Liyun Feng Yining Li Yuanzhi Ye Mingwei Fu Lihe Lu Jianyun Yan Source Type: research
Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control - from bedside to bench
Am J Physiol Cell Physiol. 2023 Jul 31. doi: 10.1152/ajpcell.00177.2023. Online ahead of print.ABSTRACTLarge placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular events in a glucose-independent manner, thereby ultimately reducing mortality in patients with chronic kidney disease (CKD) and/or heart failure. These exiting clinical data stimulated preclinical studies aiming to understand the observed clinical effects. In animal models, it was shown that the beneficial effect of SGLT2i on the tubuloglomerular fe...
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: Xin Chen Carl-Friedrich Hocher Linghong Shen Bernhard K Kr ämer Berthold Hocher Source Type: research
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy
Pharmacol Ther. 2023 Jul 24:108503. doi: 10.1016/j.pharmthera.2023.108503. Online ahead of print.ABSTRACTWe have performed a systematic review of studies reporting on the renal effects of SGLT2 inhibitors in rodent models of diabetes. In 105 studies, SGLT2 inhibitors improved not only the glycemic control but also various aspects of renal function in most cases. These nephroprotective effects were similarly reported whether treatment with the SGLT2 inhibitor started concomitant with the onset of diabetes (within 1 week), early after onset (1-4 weeks) or after nephropathy had developed (>4 weeks after onset) with the lat...
Source: Atherosclerosis - July 26, 2023 Category: Cardiology Authors: Aqsa Ashfaq Myriam Meineck Andrea Pautz Ebru Arioglu-Inan Julia Weinmann-Menke Martin C Michel Source Type: research
Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes
Circulation. 2023 Jul 25;148(4):354-372. doi: 10.1161/CIRCULATIONAHA.123.064346. Epub 2023 Jul 24.ABSTRACTSGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose and sodium in the early proximal renal tubule, but the magnitude and duration of any ensuing natriuretic or diuretic effect are the result of an interplay between the degree of upregulation of SGLT2 and sodium-hydrogen exchanger 3, the extent to which downstream compensatory tubular mechanisms are activated, and (potentially) the volume set point in individual patients. A comprehensive review and synthesis of available studies ...
Source: Circulation - July 24, 2023 Category: Cardiology Authors: Milton Packer Christopher S Wilcox Jeffrey M Testani Source Type: research
Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)
CONCLUSIONS: This prespecified sub-analysis from the PROTECT trial demonstrated that ipragliflozin treatment, compared with the standard care for T2DM, reduced two types of estimated fluid volume parameters in patients with T2DM, and the effect was maintained for 24 months. Our findings suggest that SGLT2 inhibitor treatment regulates clinical parameters incorporated into the calculating formulas analyzed and consequently fluid volume status for the long-term, and this may be at least partly associated with clinical benefits from chronic use of SGLT2 inhibitors. Trial registration Japan Registry of Clinical Trials, ID jRCT...
Source: Atherosclerosis - July 6, 2023 Category: Cardiology Authors: Atsushi Tanaka Takumi Imai Shigeru Toyoda Kazuhiro Sugimoto Ruka Yoshida Machi Furuta Koichi Node PROTECT Investigators Source Type: research
Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial
CONCLUSIONS: Tofogliflozin was not associated with improved inhibition of carotid wall thickening but exerted long-term positive effects on various cardiovascular risk factors and baPWV while showing a good safety profile.PMID:37349722 | DOI:10.1186/s12933-023-01879-4
Source: Atherosclerosis - June 22, 2023 Category: Cardiology Authors: Naoto Katakami Tomoya Mita Hidenori Yoshii Toshihiko Shiraiwa Tetsuyuki Yasuda Yosuke Okada Akira Kurozumi Masahiro Hatazaki Hideaki Kaneto Takeshi Osonoi Tsunehiko Yamamoto Nobuichi Kuribayashi Kazuhisa Maeda Hiroki Yokoyama Keisuke Kosugi Kentaro Ohtosh Source Type: research
SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases
Int J Mol Sci. 2023 May 13;24(10):8732. doi: 10.3390/ijms24108732.ABSTRACTThe purpose of this manuscript is to review the effects of sodium-glucose cotransport protein 2 inhibitors (SGLT2is) in patients with chronic kidney disease according to basic mechanisms, current recommendations, and future perspectives. Based on growing evidence from randomized, controlled trials, SGLT2is have proven their benefit on cardiac and renal adverse complications, and their indications expanded into the following five categories: glycemic control, reduction in atherosclerotic cardiovascular disease (ASCVD), heart failure, diabetic kidney d...
Source: Atherosclerosis - May 27, 2023 Category: Cardiology Authors: Assunta Di Costanzo Giovanni Esposito Ciro Indolfi Carmen Anna Maria Spaccarotella Source Type: research
